Angiotensin (1-7) Clinical Trials

Size	Price	Qty
5mg	USD 79
25mg	USD 237

Clinical Trials

A clinical trial is currently evaluating Angiotensin (1-7) for the treatment of moderate to severe traumatic brain injury. Sponsored by the University of Arizona in partnership with the United States Department of Defense, this combined Phase 1/2 study aims to assess the compound's preliminary safety profile and therapeutic efficacy. The trial is presently listed as not yet recruiting participants.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06282965	Not yet recruiting	Traumatic Brain Injury	University of Arizona\|United States Department of Defense	2024-03	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Angiotensin (1-7) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Angiotensin (1-7) acts as an endogenous bioactive peptide of the renin-angiotensin system that binds to the Mas receptor and inhibits angiotensin-converting enzyme activity, thereby suppressing downstream myostatin-mediated signaling cascades and cellular stress responses. This targeted inhibition of catabolic biochemical pathways promotes tissue protection and neurovascular recovery, providing therapeutic rationale for its evaluation in mitigating pathological cascades following traumatic brain injury.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).